Physician profile
Noel Guzman
NPI 1780604413
$9,350.71
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,097 · 2020: $1,024 · 2021: $1,868 · 2022: $1,603 · 2023: $1,622 · 2024: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,635 · Education: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,635.44 |
| Education | $122.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,632.88 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,122.35 | 2019-2023 | |
| Pfizer INC. | $897.82 | 2019-2023 | |
| Amgen INC. | $730.12 | 2019-2024 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $654.85 | 2019-2023 | Trelegy Ellipta, Bexsero, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $598.69 | 2019-2022 | |
| Lilly USA, LLC | $505.99 | 2019-2023 | Jardiance, Emgality, Mounjaro |
| Novo Nordisk INC | $482.62 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $378.63 | 2019-2024 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $315.24 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $303.98 | 2019-2022 | |
| Astellas Pharma US INC | $193.47 | 2019-2021 | |
| Cmp Pharma, INC. | $193.42 | 2021-2023 | Carospir, Tadliq, Norliqva |
| Kowa Pharmaceuticals America, INC. | $125.41 | 2019-2020 | |
| Amarin Pharma, INC. | $117.51 | 2019-2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noel Guzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.